These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25524209)

  • 1. The analysis of incontinence episodes and other count data in patients with overactive bladder by Poisson and negative binomial regression.
    Martina R; Kay R; van Maanen R; Ridder A
    Pharm Stat; 2015; 14(2):151-60. PubMed ID: 25524209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB.
    Martina R; Kay R; Abrams P; van Maanen R; Ridder A
    Neurourol Urodyn; 2016 Aug; 35(6):728-32. PubMed ID: 25932920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On performance of parametric and distribution-free models for zero-inflated and over-dispersed count responses.
    Tang W; Lu N; Chen T; Wang W; Gunzler DD; Han Y; Tu XM
    Stat Med; 2015 Oct; 34(24):3235-45. PubMed ID: 26078035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Count data distributions and their zero-modified equivalents as a framework for modelling microbial data with a relatively high occurrence of zero counts.
    Gonzales-Barron U; Kerr M; Sheridan JJ; Butler F
    Int J Food Microbiol; 2010 Jan; 136(3):268-77. PubMed ID: 19913934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary incontinence and overactive bladder in patients with heart failure.
    Palmer MH; Hardin SR; Behrend C; Collins SK; Madigan CK; Carlson JR
    J Urol; 2009 Jul; 182(1):196-202. PubMed ID: 19447424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A score test for overdispersion in zero-inflated poisson mixed regression model.
    Xiang L; Lee AH; Yau KK; McLachlan GJ
    Stat Med; 2007 Mar; 26(7):1608-22. PubMed ID: 16794991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
    Kasjan GR
    Urologiia; 2015; (4):121-4. PubMed ID: 26665779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Differential diagnosis and therapy examined under the microscope. LUTS (lower urinary tract symptoms) due to OAB (overactive bladder) - a frequent disease picture in the man].
    MMW Fortschr Med; 2011 Mar; 153(13):44-5. PubMed ID: 21638816
    [No Abstract]   [Full Text] [Related]  

  • 14. Statistical modelling of falls count data with excess zeros.
    Khan A; Ullah S; Nitz J
    Inj Prev; 2011 Aug; 17(4):266-70. PubMed ID: 21653652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomic study of using solifenacin for the treatment of urge urinary incontinence in patients with overactive bladder syndrome].
    Avksent'eva MV; Gerasimova KV; Khachatrian GR; Frolov MIu; Omel'ianovskiĭ VV; Avksent'ev NA
    Urologiia; 2014; (5):56-8, 60-1. PubMed ID: 25807761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local influence measure of zero-inflated generalized Poisson mixture regression models.
    Chen XD; Fu YZ; Wang XR
    Stat Med; 2013 Apr; 32(8):1294-312. PubMed ID: 22903860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
    Tyagi P; Tyagi V
    IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the use of zero-inflated and hurdle models for modeling vaccine adverse event count data.
    Rose CE; Martin SW; Wannemuehler KA; Plikaytis BD
    J Biopharm Stat; 2006; 16(4):463-81. PubMed ID: 16892908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized Poisson distribution: the property of mixture of Poisson and comparison with negative binomial distribution.
    Joe H; Zhu R
    Biom J; 2005 Apr; 47(2):219-29. PubMed ID: 16389919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.